| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6c47decd380b5be24cbf21065e0353c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a722744e77c81c5f5cf415087e2ee92b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ebeef7d4a3a3b0f2b011f2a8708654d6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c827b0fe5f3cb76922a2da03116db521
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aeab358608f5a0a78f44d8d6c729f115 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-71 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5044
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2842
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2009-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e278f32a6420ac2fe74af1d23c9b9e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2109ccd130fc86624280069c980a28b6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00b5703379fead82c3ddcfa0a84ad548
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be2dc3128faff80a1f8eafb27587ebc8 |
| publicationDate |
2013-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8465738-B2 |
| titleOfInvention |
Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics |
| abstract |
The present invention is directed to a method of inhibiting tumor formation in a cancer patient at a site remote from sites of prior tumor formation and to a method of preventing metastases. These methods involve administering to the cancer patient an inhibitor of vascular endothelial growth factor receptor 1 + bone marrow-derived cells under conditions effective either to inhibit tumor formation in the cancer patient at a site remote from sites of prior tumor formation or to prevent metastases. Candidate compounds useful for such purposes can be screened depending on whether they bind to vascular endothelial growth factor receptor 1 + bone marrow-derived cells. Metastases in a cancer patient can be monitored by evaluating a patient sample for detection and quantification of vascular endothelial growth factor receptor 1 + bone marrow-derived cells and comparing the level of vascular endothelial growth factor receptor 1 + bone marrow-derived cells to prior levels. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9816998-B2 |
| priorityDate |
2004-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |